As Senior Vice President of Corporate Strategy and Business Development, Chris is responsible for driving business strategy and technology commercialization across OmniSeq’s pharmaceutical services and clinical testing businesses. In this role, he is responsible for developing partnerships with pharmaceutical, biotech and research organizations to leverage OmniSeq’s multi-modal molecular testing platforms for biomarker discovery and clinical development.
Also, in partnership with key channel and distribution alliances, Chris oversees the implementation of market adoption and growth strategies for clinical testing.
With more than 25 years of global experience spanning the life sciences, clinical diagnostic, medical device and venture capital arenas, Chris has been instrumental in strategy development, product development and validation, partnerships, licensing and mergers and acquisitions across numerous organizations. Prior to joining OmniSeq, Chris was President & COO of GenomeNext, LLC and cofounded the precision medicine company around proprietary bioinformatic big-data technologies translating genetic variation, population-scale genomics and discriminative biomarker discovery into clinically actionable solutions.
Chris has held executive leadership roles with organizations commercializing differentiating technology assets across several market segments including pharma/biotech, genomics services, clinical diagnostics, and federal and military health. Prior to cofounding GenomeNext, Chris was EVP & COO of Nuclea Diagnostics, a development stage molecular diagnostics company targeting discovery and validation of novel oncology biomarker assays. Before Nuclea, he was a Director at Toucan Capital and managed portfolio investments developing commercial-stage assets around stem cell and regenerative medicine technologies. Preceding Toucan Capital, Chris managed multinational business operations and broad strategic development and M&A initiatives at Serologicals; acquired by Millipore, leveraging an extensive portfolio of drug discovery services, IVD tests and life science reagents. Earlier in his career, Chris managed diagnostic test development and GMP laboratory operations for Oncor, Inc., a pioneer in gene-based diagnostic testing and was pivotal in the development, validation and FDA approval of the HER-2/neu gene detection system, a standard of care for managing breast cancer as a predictive biomarker for potential responsiveness to therapies.
In addition to his role at OmniSeq, Chris currently serves on the board of the Foundation to Fight to H-ABC shaping funding and scientific initiatives aligning strategies to accelerate clinical development and validation targeting a cure for Leukodystrophies.